BioTuesdays

Giving healthcare companies and their stories the exposure they deserve.

Subscribe

THIS WEEK'S FEATURE

MORE FEATURES

Gregory Penner takes us into the world of aptamers

As president, a co-founder and CEO of closely-held NeoVentures Biotechnology, Gregory Penner, Ph.D., took a different route developing aptamers for healthcare solutions. His training was in quantitative genetics of crop...


NEWS

HCW starts Metacrine at buy; PT $15

H.C. Wainwright launched coverage of Metacrine (NASDAQ:MTCR) with a “buy” rating and $15 price target. The stock closed at $4.14 on June 11. Metacrine is a clinical-stage biopharmaceutical company focused on discovering...

Cantor ups RAPT Therapeutics PT to $71 from $51

Cantor Fitzgerald raised its price target for RAPT Therapeutics (NASDAQ:RAPT) to $71 from $51, citing an increased probability of success for RPT193 in atopic dermatitis to 50% from 25% previously, and taking up peak...

Cantor starts CareCloud at OW: PT $15

Cantor Fitzgerald launched coverage of CareCloud (NASDAQ:MTBC) with an “overweight” rating and $15 price target. The stock closed at $8.54 on June 10. CareCloud, formerly known as MTBC Inc., provides a broad range of...

AGP starts Myomo at buy; PT $36.50

Alliance Global Partners initiated coverage of Myomo (NYSEA:MYO) with a “buy” rating and price target of $36.50. The stock closed at $10.19 on June 9. “Myomo, in our view, represents one of the most compelling stories...

HCW starts UNITY Biotechnology at buy; PT $12

H.C. Wainwright launched coverage of UNITY Biotechnology (NASDAQ:UBX) with a “buy” rating and $12 price target. The stock closed at $4.56 on June 4. UNITY is focusing on therapeutics addressing diseases of aging, while...


Just a few of the companies we’ve highlighted along the way

coverage